REFLECTIONS FROM MUNICH: A SUMMIT ON LIFE SCIENCES STRATEGY ON IP & EXCLUSIVITY
This past week in Munich, our founder Keisha Hylton-Rodic participated in the panel Divisional Patenting in Europe and the USA: How Can Originators and Generics Navigate the Current Legal Landscape? alongside distinguished colleagues Ina Bürck, Julia Pike, Mathilde Rauline, and Dr. Maurizio Di Stasio.
As the 2025 edition of the Life Sciences Strategy Summit on IP & Exclusivity made clear, the intersection of originator- and generic-led innovation, exclusivity strategy, and global regulatory shifts is more dynamic and more critical than ever.
Key Takeaways from the Session
The panel highlighted how divisional patenting is no longer a niche procedural topic: it’s increasingly central to navigating both European and U.S. exclusivity landscapes.
The conversation reinforced something we live by at Hylton-Rodic Law: when originators and generics engage in meaningful dialogue, the outcome is not simply “either/or” but progress for the entire life-sciences ecosystem, better patient access, stronger portfolios, and smarter risk-management.
As reflected, what makes this work so rewarding is when “nuance, challenge, and collaboration all roll into one”. The session ran out of time just when the debate was heating up, a sure sign of sharp minds and deep engagement.
Importantly, the summit’s agenda confirmed the breadth of the conversation: from SPC waiver effects, to UPC implications, to patent quality and enablement in the life-sciences field.
Why This Matters for Our Clients
At Hylton-Rodic Law, we translate insights like these into actionable strategies. Whether you’re navigating divisional filings, defending challenging patents, or planning entry-to-market in the originator/generic transition space, the themes from Munich underscore three imperatives:
Proactive engagement: Don’t merely react to jurisprudence or regulation; anticipate how decisions on divisional strategy or exclusivity will affect your position.
Cross-sector perspective: Success requires seeing beyond “just patents” or “just generics”; the interface of IP, regulation, competition, and business model matters.
Partnership mindset: Real-world progress comes when generics and originators, counsel and industry, exchange insight rather than silo themselves.
What’s Next?
As the conversation continues beyond the conference, we invite you to reach out for a deeper discussion:
Want to evaluate your divisional filing strategy in the U.S.?
Facing upcoming regulatory or exclusivity deadlines that could impact generics or biosimilars?
Curious how global patent-litigation trends and regulatory shifts will affect your exclusivity horizon?
We’re ready to help you turn the insights from Munich into your next move.
